Comparative safety and efficacy of a sirolimus-eluting versus paclitaxel-eluting stent: A meta-analysis

American Heart Journal

Volumn 155, Issue 4, 2008, Pages 630-639

  Gurm, Hitinder S ^a   Boyden, Thomas ^a   Welch, Kathy B ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETES MELLITUS; DRUG ELUTING STENT; FOLLOW UP; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; PACLITAXEL ELUTING STENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; SIROLIMUS ELUTING STENT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS;

CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS;

EID: 40849150745     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.11.021     Document Type: Article

References (33)

1. Babapulle M.N., Joseph L., Belisle P., et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
2. Williams D.O., Abbott J.D., and Kip K.E. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 114 (2006) 2154-2162
3. Silber S. Cypher versus Taxus: are there differences?. J Interv Cardiol 18 (2005) 441-446
4. Juni P., Witschi A., Bloch R., et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282 (1999) 1054-1060
5. Sankey S., Weissfeld L., Fine M., et al. An assessment of the use of the continuity correction for sparse data in meta-analysis. Commun Stat Simulation Comput 25 (1996) 1031-1056
6. Smeeth L., Haines A., and Ebrahim S. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 318 (1999) 1548-1551
7. Jackson R.T., and Sackett D.L. Guidelines for managing raised blood pressure. BMJ 313 (1996) 64-65
8. Orwin R. A fail-safe N for effect size in meta-analysis. J Educ Stat 8 (1983) 157-159
9. Rosenberg M.S. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. Evol Int J Org Evol 59 (2005) 464-468
10. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
11. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
12. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
13. Goy J.J., Stauffer J.C., Siegenthaler M., et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 45 (2005) 308-311
14. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
15. Kim Y.H., Park S.W., Lee S.W., et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 114 (2006) 2148-2153
16. Mehilli J., Dibra A., Kastrati A., et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
17. Morice M.C., Colombo A., Meier B., et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
18. Cervinka P., Costa M.A., Angiolillo D.J., et al. Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study. Catheter Cardiovasc Interv 67 (2006) 846-851
19. Lee J., Kim H., Lee S., et al. Randomised trial of sirolimus versus paclitaxel eluting stent for the treatment of acute ST elevation myocardial infarction. J Am Coll Cardiol 47 4(Suppl A) (2006) 184
20. de Lezo J., Medina A., Pan M., et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. [abstract]. J Am Coll Cardiol 45 Suppl A (2005) 75A
21. http://www.tctmd.com/csportal/appmanager/tctmd/tct2006?_nfpb=true&_pageLabel=TCT2006Content&hdCon=1453766 (accessed December 30, 2006, link inactive).
22. Wessely R., Schomig A., and Kastrati A. Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 47 (2006) 708-714
23. Levin A.D., Vukmirovic N., Hwang C.W., et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A 101 (2004) 9463-9467
24. Hwang C.W., Levin A.D., Jonas M., et al. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 111 (2005) 1619-1626
25. Ellis S.G., Popma J.J., Lasala J.M., et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1193-1200
26. http://www.theheart.org/article/702271.do (accessed December 23, 2006).
27. Roiron C., Sanchez P., Bouzamondo A., et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 92 (2006) 641-649
28. Kereiakes D.J., Kuntz R.E., Mauri L., et al. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 45 (2005) 1206-1212
29. Mauri L., Orav E.J., O'Malley A.J., et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 111 (2005) 321-327
30. Sidhu S., Shafiq N., Malhotra S., et al. A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol 61 (2006) 720-726
31. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
32. Stone G.W., Ellis S.G., O'Shaughnessy C.D., et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 295 (2006) 1253-1263
33. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591